

1 PROVIDER INFORMATION

Account Name _____
 Address _____
 Phone _____ Fax _____
 Provider Name _____
 NPI# _____
 Results Delivery Preference Fax Mail

2 PRESCRIBER ATTESTATIONS

My signature below indicates:

ACKNOWLEDGMENT OF INFORMED CONSENT FOR GENETIC TESTING

I have reviewed and obtained the proper genetic consent required from my patient for the state in which I practice (NY state requirements provided on back page of form).

ACKNOWLEDGMENT OF CLINICAL EXPERIENCE TESTING

I am ordering this test under a limited clinical experience testing program and I will not seek payment for or accept reimbursement from any third-party payer for this test. I attest that the patient receiving this testing is **NOT** covered by any government program such as Medicare, Medicaid, Department of Veterans Affairs, Coast Guard, Public Health Service, Department of Defense or any similar or affiliated program.

ACKNOWLEDGMENT OF PATIENT DATA & RISK PROFILE USE

I have informed the patient that his/her data and risk profile will be used to characterize use of CDPATH™ in the real world setting.

→ PROVIDER SIGNATURE _____ DATE _____

3 PATIENT INFORMATION

Last Name _____ First Name _____ DOB _____ Sex F M
 Address Line 1 _____ Address Line 2 _____
 City _____ State _____ ZIP _____
 Primary Phone _____ Secondary Phone _____

Patient **MUST** be ≥18 years old with Crohn's disease

4 CDPATH™ TESTING ONLY. NO SUBSTITUTIONS.

CHECK BOX BELOW TO ORDER CDPATH TEST

CDPATH – #2050

MUST COMPLETE ALL BOXES TO ORDER CDPATH TEST

CLINICAL DIAGNOSIS

ICD-10 code (must be Crohn's disease code): _____

Date of Crohn's diagnosis: _____

mm / dd / yyyy

If diagnosed >10 years ago, patient is **NOT** eligible →



DISEASE HISTORY

Does patient have a history of serious complications?

- bowel strictures • internal penetrating disease
- non-perianal surgery, such as bowel resection or stricturoplasty

YES → If YES, patient is **NOT** eligible →

NO



DISEASE LOCATION(S)

Must check **PRESENT** or **ABSENT** for each based on **greatest extent** of disease since diagnosis

	Present	Absent		Present	Absent		Present	Absent
Small bowel	<input type="checkbox"/>	<input type="checkbox"/>	Perianal	<input type="checkbox"/>	<input type="checkbox"/>	Right colon	<input type="checkbox"/>	<input type="checkbox"/>
Left colon	<input type="checkbox"/>	<input type="checkbox"/>	Upper GI tract	<input type="checkbox"/>	<input type="checkbox"/>	Transverse colon	<input type="checkbox"/>	<input type="checkbox"/>

CDPATH RISK-ASSESSMENT TEST INCLUDES: (No selection required)

- | | |
|----------------------|--------------------|
| Serologic Biomarkers | Genetic Biomarkers |
| • ASCA IgA | • Anti-CBir1 IgG |
| • ASCA IgG | • pANCA IFA |
| | • NOD2 (1007FS) |

Terms and Conditions: CDPATH is only validated in and can only be run on adult Crohn's disease patients (≥18 years old), diagnosed within the past ten (10) years, who have not experienced a Crohn's disease complication such as blockages, strictures or fistulas. Any requisitions which fail to meet these requirements will be canceled upon receipt. Beneficiaries of any state or federal health insurance program (including, but not limited to, Medicare, Medicaid, Department of Veterans Affairs, Coast Guard, Public Health Service or Department of Defense) are excluded from participating in this program. Void where prohibited by law. Takeda reserves the right to change or end CDPATH at any time without notice, and other terms and conditions may apply. This test cannot be substituted for or combined with any other test and is only offered for a one-time use. By using the CDPATH test requisition, you are specifically requesting that your patient's specimen be sent to Prometheus Laboratories Inc. for testing and asking that no alternative test be performed.

5 SAMPLE COLLECTION INFORMATION

Date Collected _____
 Time Collected _____
 Patient ID _____
 Sender Sample ID _____

6 SENDING LABORATORY INFORMATION

Laboratory/Other Name _____
 Address _____
 Phone _____ Fax _____
 Contact _____
 Results Delivery Preference Fax Mail No results to lab

7 ATTENTION LABORATORY

- Takeda has made arrangements with the healthcare provider (HCP) listed above to provide the CDPATH test at no charge in order for the HCP to gain clinical experience with the test.
- Only CDPATH can be ordered using this form.
- Please do not collect or process any insurance claims for this test.

- NO CHARGES should be billed to the patient for this test. Prometheus will not bill for testing or services related to testing.
- Specimen transportation kits containing pre-paid air bills can be provided upon request.

QUESTIONS?

Contact CDPATH Client Services at Prometheus Laboratories Inc.
 Monday - Friday, 6:00 AM - 4:30 PM Pacific Standard Time
 Toll-free: 877-556-8766 • Fax: 877-816-4019
 9410 Carroll Park Drive, San Diego, CA 92121
Specimen collection requirements on back.



Program sponsored by
Takeda Pharmaceuticals U.S.A., Inc.



Laboratory Developed Test by
Prometheus Laboratories Inc.

SPECIMEN COLLECTION AND HANDLING PROCEDURES

Test Ordered Turnaround Time From Sample Collection Date	Specimen Requirements	Recommended Specimen Volume	Specimen Storage/Stability	Transportation Kit Requirements
CDPATH 7 business days	SERUM AND WHOLE BLOOD in Spun Serum Separator or Red-Top Tube AND EDTA/Lavender-Top Tube	2.0 mL serum AND 2.0 mL whole blood	Room temp: 7 days	Ambient pack

Specimens should be labeled with 2 identifiers and date of collection. Examples of acceptable identifiers include, but are not limited to, patient name, date of birth, hospital number, requisition, accession, or unique random number. Unlabeled specimens will not be accepted for testing.

SHIPPING INSTRUCTIONS: Prometheus Laboratories Inc. has an agreement with FedEx® Express for priority overnight delivery service within the United States. Please call FedEx to schedule a pickup at 1-800-GoFedEx (1-800-463-3339). FedEx will pick up your specimens and ship them to Prometheus in San Diego at no expense to you. Prometheus will provide specimen transportation kits upon request. NOTE: Multiple specimens may be shipped in a single transportation kit.

ACKNOWLEDGMENT OF INFORMED CONSENT FOR GENETIC TESTING

Please confirm the genetic testing requirements in your state prior to signing the acknowledgment on the first page.

If you are practicing in New York State, the following information reflects the New York State's requirements for informed genetic testing.

I warrant that this test was ordered and that I have obtained the appropriate prior written consent. This written consent was signed by the person who is the subject of the test (or if that person lacks capacity to consent, signed by the person authorized to consent for that person).

1. The purpose of this test is to determine if the patient may have a variant in the gene(s) being tested, which has been found to be associated with this condition.
2. This test will only test for this specific condition and will not detect ALL possible variants within this gene, nor will it detect variants in other genes.
3. Prior to my signature of the written consent, a qualified healthcare professional discussed with the patient the genetic test ordered and described the steps involved in the test, the constraints of the procedure, and its accuracy.
4. My patient was advised by a qualified healthcare professional of the risks and benefits of genetic testing, and advised of the significance of a positive and negative result.
5. The patient understands that a positive test result is an indication that the patient may be predisposed to, or have, the condition listed above.
6. If the results are positive, the patient understands that he/she may wish to consider further independent testing, consult his/her provider, or pursue genetic counseling.
7. The patient understands that the test may fail, that the results may be non-informative or not predictive for his/her case, and that the test may reveal information that is unrelated to their intended purpose.
8. No unauthorized test is performed on specimens.
9. Specimens will be destroyed within 60 days after collection when no longer required for clinical purposes.
10. The informed consent does not authorize the use or release of any other identified medical information unrelated to this genetic test.
11. The patient understood that he/she could see professional genetic counseling prior to undergoing the testing procedure, and received written information identifying a genetic counselor or medical geneticist by his/her treating provider.

QUESTIONS?

Contact CDPATH Client Services at 877-556-8766

Operating hours: Monday - Friday, 6:00 AM - 4:30 PM Pacific Standard Time

CDPATH is a laboratory-developed test that was developed, validated and is performed under Federal CLIA laboratory guidelines exclusively by Prometheus Laboratories Inc. CDPATH™ is a trademark of Takeda Pharmaceuticals U.S.A., Inc. PROMETHEUS is a trademark of Prometheus Laboratories Inc. All other trademarks or service marks are the property of their respective owners.